Covidien's strong Q2 builds on good start to 2012; acquires hernia device firm
This article was originally published in Clinica
Executive Summary
Covidien's good start to 2012 has continued into its second fiscal quarter, as the firm reported group revenues of $2.95bn for that period, up 5% year-on-year. Medical devices, the firm's biggest division, saw sales growth of 7% to $2.0bn during Q1, again outperforming Covidien's soon-to-be-spun-out pharmaceuticals (+4% to $508m) and medical supplies divisions (flat at $434m).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.